Filed March 7, 2018

Serial No. 87824828

Registered May 21, 2019

Registration No. 5,754,634

Class Pharmaceutical and medicinal preparations and substances for the treatment of [ cancer, thrombosis, embolisms, inflammation, autoimmune diseases, and ] envenomation by snakes; veterinary preparations and substances for the treatment of envenomation by snakes; sanitary preparations for medical purposes; dietetic foods adapted for medical use; vaccines; antitoxic sera; medical diagnostic reagents and substances, all for in vivo use; [ Antibodies being therapeutic antibodies for use as anti-lymphocytic agents; pharmaceutical preparations in the form of foams or for use in producing foams for the treatment of sclerotherapy, phlebology, angiology or proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; chemical reagents for medical or veterinary purposes; ] chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes, methotrexate toxicity, 5-fluorouracil toxicity; chemico-pharmaceutical preparations for the treatment of envenomation by snakes; [ chemical preparations for medical or pharmaceutical purposes for use in the prevention and treatment of cancer, circulatory system issues and conditions, pulmonary embolisms, thrombus, deep vein thrombosis, peripheral arterial occlusions, blood clots, vascular issues and conditions, intracranial hemorrhages, cerebral hemorrhages, hematomas, and as antidotes; pharmaceutical preparations for the treatment of cancer; ] pharmaceutical and veterinary preparations for the reduction or elimination of circulating cytokines; pharmaceutical and veterinary preparations for the treatment of digoxin, digitalis or other cardio-active glycoside toxicity; pharmaceutical and veterinary preparations for treatment of envenomation by snakes; pharmaceutical preparations for the treatment of methotrexate toxicity; pharmaceutical preparations for the treatment of immune disorders; [ pharmaceutical preparations for the treatment of cancer including prostate, oesophageal and brain cancer and leukaemias; pharmaceutical preparations for the treatment of sepsis; ] preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations and substances for use in the circulatory system; [ pharmaceutical preparations and substances for embolization; pharmaceutical preparations and substances for embolization of tumours and arteriovenous malformations (AVMs); pharmaceutical preparations and substances for use in the circulatory system for the treatment of tumours and AVMs; ] adjuvants for medicinal purposes, vaccine adjuvants and vaccine preparations containing adjuvant; chemical reagents for medical or veterinary purposes for the treatment of envenomation by snakes; chemical reagents for therapeutic and diagnostic purposes for the treatment of envenomation by snakes; chemical preparations for medical or pharmaceutical purposes for the treatment of envenomation by snakes; medicines for the treatment of envenomation by snakes; [ pharmaceutical and veterinary preparations for the treatment of pre-eclampsia; chemical reagents for medical or veterinary therapeutic and medical diagnostic purposes; ] chemico-pharmaceutical preparations for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity [ , and for use in the treatment of pre-eclampsia ] ; chemical preparations for medical or pharmaceutical purposes and medicines for use in the treatment of digoxin, digitalis or other cardio-active glycoside toxicity [ and for use in the treatment of pre-eclampsia ] ; [ transarterial chemoembolization pharmaceutical preparations, vaccines and antitoxic sera; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; irradiated or radioactive microspheres used for in vivo therapeutic medical purposes; radiotherapy substances for medical purposes, namely, radioactive pharmaceutical preparations for medical purposes for the treatment of cancer; radiopharmaceuticals, namely, radiopharmaceuticals for the treatment of cancer and radiopharmaceutical preparations for use in nuclear medicine; therapeutic agents for delivery of radioactive material to target sites within the body; pharmaceutical preparations, being beads, including microscopic radioactive beads, for treatment of cancerous tumours; pharmaceutical preparations, being beads, including microscopic glass beads, impregnated with radioactive material for treatment of cancerous tumours; pharmaceutical preparations, being beads, namely, radioactive glass beads; pharmaceutical preparations for use with ultrasound waves to enhance drug delivery and/or medically activate drugs; pharmaceutical preparations in the form of foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams for use in producing foams for use in sclerotherapy treatment of veins; pharmaceutical preparations in the form of foams or for use in producing foams for sclerotherapy, phlebology, angiology and proctology, for treatment of oesophageal varices, hydroceles, in sterilisation treatment or for treatment of varicose veins, or arterio-venous malformations; ] pharmaceutical preparations containing methotrexate antidotes for the treatment of methotrexate toxicity; pharmaceutical preparations containing 5-fluorouracil antidotes for the treatment of 5-fluorouracil toxicity; pharmaceutical preparations for use in chemotherapy and autoimmune diseases; pharmaceutical preparations used for regulating toxicity levels of therapeutic agents; pharmaceutical preparations used for depleting concentrations of therapeutic agents; 006; 018; 044; 046; 051; 052; 026; 039; 044; 100; 101; 107

Case Type Trademark Service mark